CINXE.COM

<!DOCTYPE html><html lang="en"><head><link rel="stylesheet" data-href="https://fonts.googleapis.com/css?family=Roboto+Slab%7COpen+Sans%7CRoboto&display=swap" data-optimized-fonts="true"/><title>Prostate cancer: new screening measures and decreasing mortality rates</title><link rel="icon" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png"/><link rel="shortcut icon" type="image/x-icon" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png?optimizer=image&format=webp&width=180&aspectRatio=1"/><link rel="apple-touch-icon" sizes="180x180" href="https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png?optimizer=image&format=webp&width=180&aspectRatio=1"/><link rel="canonical" href="/domains/magazine.pharmafile.com/articles/prostate-cancer-new-screening-measures-and-decreasing-mortality"/><meta name="application-name" content="Prostate cancer: new screening measures and decreasing mortality rates"/><meta name="apple-mobile-web-app-capable" content="yes"/><meta name="apple-mobile-web-app-status-bar-style" content="default"/><meta name="apple-mobile-web-app-title" content="Prostate cancer: new screening measures and decreasing mortality rates"/><meta name="format-detection" content="telephone=no"/><meta name="mobile-web-app-capable" content="yes"/><meta name="msapplication-TileColor" content="#1976D2"/><meta name="msapplication-tap-highlight" content="no"/><link rel="manifest" href="/manifest.json"/><meta name="twitter:url" content="https://magazine.pharmafile.com"/><meta name="theme-color" content="#1976D2"/><meta name="viewport" content="width=device-width, initial-scale=1"/><meta charSet="utf-8"/><meta itemProp="name" content="Prostate cancer: new screening measures and decreasing mortality rates"/><meta name="keywords" content="Prostate cancer: new screening measures and"/><meta itemProp="description" content="Professor hendrik van poppel talks to pharmafile about new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what"/><meta name="description" content="Professor hendrik van poppel talks to pharmafile about new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what"/><meta itemProp="image" content="https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg"/><meta property="og:description" content="Professor hendrik van poppel talks to pharmafile about new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what"/><meta property="og:title" content="Prostate cancer: new screening measures and decreasing mortality rates"/><meta property="og:site_name" content="Prostate cancer: new screening measures and decreasing mortality rates"/><meta property="og:image" content="https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg"/><meta property="og:type" content="website"/><meta name="twitter:card" content="summary_large_image"/><meta name="twitter:title" content="Prostate cancer: new screening measures and decreasing mortality rates"/><meta name="twitter:description" content="Professor hendrik van poppel talks to pharmafile about new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what"/><meta name="twitter:image" content="https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg"/><meta name="author" content="Pharmafile"/><meta property="article:author" content="Pharmafile"/><meta property="article:published_time" content="2023-10-01T00:00:00.000Z"/><meta name="twitter:site" content="@pharmafocus"/><meta name="twitter:creator" content="@pharmafocus"/><style>html{--heading-font: "Roboto Slab";--body-font: "Open Sans";--ui-font: "Roboto";--top-menu-title-font: "Roboto Slab";--top-menu-subtitle-font: "Roboto";--top-menu-items-font: "Roboto";--footer-menu-title-font: "Roboto Slab";--footer-menu-items-font: "Roboto";--background-color: #FFFFFF;--background-color-dark: #808080;--primary-color: #1976D2;--primary-color-dark: #0C3B69;--secondary-color: #795FF4;--secondary-color-dark: #250B9F;--accent-color: #D76FD6;--accent-color-dark: #80237F;--info-color: #41638C;--info-color-dark: #213246;--warning-color: #EF9338;--warning-color-dark: #89490B;--success-color: #20AD27;--success-color-dark: #105714;--danger-color: #DF4241;--danger-color-dark: #7B1515;--top-menu-background-color: #FFFFFF;--top-menu-background-color-dark: #808080;--footer-menu-background-color: #000000;--footer-menu-background-color-dark: #000000;--top-menu-heading-title-color: #000000;--top-menu-heading-title-color-dark: #000000;--top-menu-item-text-color: #000000;--top-menu-item-text-color-dark: #000000;--top-menu-item-icon-color: #000000;--top-menu-item-icon-color-dark: #000000;--navbar-height: 64px; }</style><link rel="stylesheet" data-href="https://use.typekit.net/nat8xfl.css" data-optimized-fonts="true"/><script type="text/javascript" src="https://cdn.jsdelivr.net/npm/cookie-bar/cookiebar-latest.min.js?customize=1&always=1&showNoConsent=1"></script><meta name="google-site-verification" content="1Gr9skOzVfL3FXDYTam8oONdREeoeMCoQWnlojFJHX0"/><style> #billboard-banner { text-align:center;} #billboard-banner img {width:100%; max-width:970px; height:auto; position:relative; top:70px;} </style><meta name="next-head-count" content="43"/><link rel="preconnect" href="https://fonts.googleapis.com"/><link rel="preconnect" href="https://fonts.gstatic.com"/><link rel="preload" href="/_next/static/css/229efe2956472d85.css" as="style"/><link rel="stylesheet" href="/_next/static/css/229efe2956472d85.css" data-n-g=""/><link rel="preload" href="/_next/static/css/7c74bf24f71f6c9d.css" as="style"/><link rel="stylesheet" href="/_next/static/css/7c74bf24f71f6c9d.css" data-n-p=""/><link rel="preload" href="/_next/static/css/eaa0062c2481f7ca.css" as="style"/><link rel="stylesheet" href="/_next/static/css/eaa0062c2481f7ca.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script defer="" src="https://fonts.googleapis.com/css?family=Open+Sans&display=swap" data-nscript="beforeInteractive"></script><script src="/_next/static/chunks/webpack-b653c683a51d8b57.js" defer=""></script><script src="/_next/static/chunks/framework-73b8966a3c579ab0.js" defer=""></script><script src="/_next/static/chunks/main-34cb81d5753e1fc4.js" defer=""></script><script src="/_next/static/chunks/pages/_app-9cc101b503fd5646.js" defer=""></script><script src="/_next/static/chunks/ad273671-3092333ffa02af02.js" defer=""></script><script src="/_next/static/chunks/876-c944523f292a2885.js" defer=""></script><script src="/_next/static/chunks/223-fe6833f316a5a95f.js" defer=""></script><script src="/_next/static/chunks/174-d95909d2aa5e8ec8.js" defer=""></script><script src="/_next/static/chunks/302-d0f1826200f9f2a4.js" defer=""></script><script src="/_next/static/chunks/pages/domains/%5Bdomain%5D/articles/%5Bslug%5D-12d0888066c7f18b.js" defer=""></script><script src="/_next/static/1bBCYhXOG7wsYuaBifvjK/_buildManifest.js" defer=""></script><script src="/_next/static/1bBCYhXOG7wsYuaBifvjK/_ssgManifest.js" defer=""></script><style data-styled="" data-styled-version="5.3.9"></style><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto+Slab%7COpen+Sans%7CRoboto&display=swap"/><link rel="stylesheet" href="https://use.typekit.net/nat8xfl.css"/></head><body><div id="__next"><div class="Layout_container__gktH6"><div class="Layout_navbar-container__gCfDZ" style="height:64px"><nav class="_wrapper_jbnbd_1"><div class="_container_jbnbd_15"><div class="_navbar-prefix_jbnbd_108"><div class="Layout_prefix__7W2Vq"><button><div class="_nav-arrow-left_1lm7t_183 _icon_1lm7t_1 icon"></div></button></div></div><a class="_navbar-brand_jbnbd_29" aria-label="Pharmafile" href="/"><div class="_navbar-image_jbnbd_40"><img alt="Logo" loading="lazy" decoding="async" data-nimg="fill" class="_image_jbnbd_43" style="position:absolute;height:100%;width:100%;left:0;top:0;right:0;bottom:0;color:transparent" sizes="100vw" srcSet="https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 54w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 70w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 82w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 96w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 110w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 128w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 138w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 192w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 200w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 252w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 260w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 298w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 378w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 384w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 520w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 640w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 756w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 828w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1080w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1200w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 1920w, https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png 2048w" src="https://media.magloft.app/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png"/></div><div class="_navbar-title_jbnbd_58 _navbar-title-hide_jbnbd_101"><span>Therapeutic areas in focus</span></div></a><div id="navbar-children-container" class="_navbar-children_jbnbd_116"><div class="_menu_1jhrl_1"><div class="_menu-wrapper_1jhrl_22"><div class="_menu-items_1jhrl_38"><a class="_menu-item_1jhrl_38" href="/"><div class="_menu-home_1lm7t_255 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Home</div><div class="_indicator_1jhrl_63"></div></a><a class="_menu-item_1jhrl_38 _active_1jhrl_70" href="/articles"><div class="_menu-articles_1lm7t_259 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Articles</div><div class="_indicator_1jhrl_63 _active_1jhrl_70"></div></a><a class="_menu-item_1jhrl_38" href="/collections"><div class="_menu-issues_1lm7t_263 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Issues</div><div class="_indicator_1jhrl_63"></div></a><a class="_menu-item_1jhrl_38" href="/account/login"><div class="_menu-account_1lm7t_411 _menu-item-icon_1jhrl_97 _icon_1lm7t_1 icon"></div><div class="_menu-item-title_1jhrl_88">Log in</div><div class="_indicator_1jhrl_63"></div></a></div></div></div></div><div id="navbar-suffix" class="_navbar-suffix_jbnbd_108"><div class="Layout_menu-actions__vsDbI"><div class="Layout_install-button__FBfSr"><div class="Tooltip_tooltip__98Sw9"></div><button class="_button_19h3g_1 _text_19h3g_12 _medium_19h3g_38 _secondary_19h3g_22" type="button" style="color:var(--top-menu-item-icon-color, var(--background-color))" role="button" aria-label="Search" aria-labelledby="labeldiv" title="Search"><div class="_action-search_1lm7t_15 _icon-button_19h3g_19 _icon_1lm7t_1 icon" style="background-color:var(--top-menu-item-icon-color, var(--background-color))"></div></button></div></div></div></div></nav></div><div class="Layout_main__evUHx"><div class="Layout_spacer__qTBD3" style="height:64px"></div><div class=""><div class=""></div><div class=""><div id="print-article" class="_slug__article__BPEHu"><div class="Article-module_article__kO4b9"><div id="outer" data-widget="page-widget" style="background-color:#FFFFFF;padding:16px 0px 24px 0px;color:#000000;text-align:left;font-family:"Open Sans"" class="Widget-module_outer__PBh8P Page-module_outer__g0XXH"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>ONCOLOGY</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h2><span style="font-family:"Roboto Slab"" class="__bold">Prostate cancer: new screening measures and decreasing mortality rates</span></h2></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold"><span style="color:rgb(0, 169, 158)">Professor Hendrik Van Poppel talks to </span><span class="__italic" style="color:rgb(0, 169, 158)">Pharmafile </span><span style="color:rgb(0, 169, 158)">about new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what obstacles still need to be addressed in treatment</span></span></p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h5><span class="__italic" style="color:rgb(38,37,35)"><span class="__bold">Pharmafile: </span></span><span style="color:rgb(38,37,35)"><span class="__bold">Tell us about the new screening measures that the Let’s Talk Prostate Cancer (LTPC) Expert Group is suggesting should be implemented across the EU.</span></span><span class="__italic" style="color:rgb(38,37,35)"> </span></h5></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">Professor Dr Hendrik Van Poppel (HVP): </span>Prostate cancer is the most frequently diagnosed cancer among men in Europe but, if it is caught in the early stages, patients are able to access additional treatment options and experience more manageable side effects. Effective early detection is paramount in reducing the morbidity and mortality rate of prostate cancer.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>So, publication of Europe’s <span class="__italic">Beating Cancer Plan </span>and of the updated EU cancer screening guidelines, along with the renewed focus on EU health policy, all mark important steps towards the eradication of inequalities in cancer diagnosis and treatment.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>The new screening guidelines should support Member States in ensuring that 90% of the EU population who qualify for breast, cervical and colorectal cancer screenings are offered such screening by 2025. For the first time, the new recommendation calls for population-based organised cancer screening to include lung, prostate and, under certain circumstances, gastric cancers.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>This is why we are making an urgent call for EU member states to implement risk-based prostate cancer screening recommendations in national cancer plans, because outcomes for future patients of prostate cancer would improve if this step is prioritised by national policymakers.</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h5><span class="__italic" style="color:rgb(38,37,35)"><span class="__bold">Pharmafile: </span></span><span style="color:rgb(38,37,35)"><span class="__bold">What are the reasons behind the poor uptake in prostate cancer screening?</span></span><span class="__italic" style="color:rgb(38,37,35)"> </span></h5></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">HVP: </span>There has been a relative decline in prostate specific antigen (PSA)-based population screening programmes for prostate cancer in Europe. The most important issue was the overdiagnosis and overtreatment of prostate cancer, which in 2012 led the US Preventive Services Taskforce to recommend against PSA testing.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Sadly, this now means we are seeing higher rates of metastatic disease and advanced prostate cancer at time of diagnosis, which in turn is associated with an increase in mortality and poorer quality of life. The situation is compounded by men feeling uncomfortable to talk about their health or to take the initiative. In many cases, they may not be aware of what their prostate is or the need to be aware of their health, particularly as they age, or if they are part of high-risk groups such as Black men and men with a family history of the disease.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>The new cancer screening recommendation is based on PSA testing to identify men at high risk of disease. These men would not undergo biopsy immediately (as before) but would receive an MRI at follow-up and this, combined with active surveillance, is expected to significantly reduce overdiagnosis and overtreatment.</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h5><span class="__italic" style="color:rgb(38,37,35)"><span class="__bold">Pharmafile: </span></span><span style="color:rgb(38,37,35)"><span class="__bold">As the most frequently diagnosed cancer in men, what is leading to the increased mortality from prostate cancer? And what can be done to combat this?</span></span><span class="__italic" style="color:rgb(38,37,35)"> </span></h5></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">HVP: </span>The COVID-19 pandemic had a significant impact on prostate cancer as it delayed both screening and treatment for patients, resulting in a record number of advanced prostate cancer cases. In fact, a recent report from the <span class="__italic">Lancet Oncology Commission </span>states that the disastrous effects of the pandemic on early diagnosis and treatment could set back cancer outcomes in Europe by almost a decade, making urgent action a crucial priority.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>Coupled with this, prostate cancer has been relatively low on the health policy agenda of the EU. Early detection is absolutely critical to improve patient outcomes and reduce mortality. It’s important that we work with national and international policymakers to prioritise prostate cancer on political agendas and dismantle stigma around the disease – it’s often viewed as an ‘old man’s disease’, or men just simply think it won’t happen to them, but prostate cancer is a killer. To do this we need to ensure there are better resources so patients, partners and families can be fully informed about prevention, diagnosis, treatment and ongoing care. It is only by detecting cancer at earlier stages that it will be possible to reduce mortality and improve the quality of life of patients.</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h5><span class="__italic" style="color:rgb(38,37,35)"><span class="__bold">Pharmafile: </span></span><span style="color:rgb(38,37,35)"><span class="__bold">Which factors will be assessed by a risk-based screening system? And how can this ensure that as many cases of prostate cancer as possible are detected?</span></span><span class="__italic" style="color:rgb(38,37,35)"> </span></h5></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">HVP: </span>The new recommendations mean prostate cancer screening should be systematically implemented, using PSA testing and magnetic resonance <span>imaging (MRI) scanning as a follow-up, in males at greater risk of prostate cancer. The screening recommendation is paying particular attention to equal access to screening and targeting the needs of particular socio-economic groups, people with disabilities and people living in rural or remote areas. Helpfully, the use of new technologies such as AI can enable the rapid processing of health data, which supports better targeted screening and may ultimately lead to quicker diagnoses.</span></p></div></div><div id="outer" data-widget="image-widget" style="background-color:transparent;padding:8px 24px 16px 24px;min-height:auto" class="Widget-module_outer__PBh8P"><div id="inner" class="Image-module_container__8raIv Image-module_container-noflex__-J1PG" style="border-radius:0px 0px 0px 0px;width:100%;min-height:auto"><picture class="Image-module_picture__gw1zY Image-module_loading__FfyPr"><source type="image/jpeg" srcSet="https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg?optimizer=image&width=192 192w,https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg?optimizer=image&width=384 384w,https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg?optimizer=image&width=768 768w,https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg?optimizer=image&width=1536 1536w" sizes="(min-width: 768px) 768px, 100vw"/><img src="https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg?optimizer=image&width=768" srcSet="https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg?optimizer=image&width=192 192w,https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg?optimizer=image&width=384 384w,https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg?optimizer=image&width=768 768w,https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg?optimizer=image&width=1536 1536w" sizes="(min-width: 768px) 768px, 100vw" class="Image-module_image__w4slc" width="100%" height="579" decoding="async" alt="Image" style="height:auto;width:100%"/></picture></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h5><span class="__italic" style="color:rgb(38,37,35)"><span class="__bold">Pharmafile: </span></span><span style="color:rgb(38,37,35)"><span class="__bold">What are the greatest risk factors of prostate cancer? And should there be more focus on spreading awareness of these factors to help with early detection?</span></span><span class="__italic" style="color:rgb(38,37,35)"> </span></h5></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">HVP: </span>The greatest risk factors for prostate cancer are age, being a Black man of African or Caribbean descent or having a family history of the disease. Unfortunately, studies show that an increasing proportion of individuals are diagnosed with metastatic or late-stage prostate cancer, so raising awareness is vital if we are to see the situation improve. In addition, ensuring the new cancer screening recommendations are implemented in full by every country within the EU will be critical alongside supporting health systems to treat patients holistically, with multidisciplinary teams and complementary therapies, like counselling, physiotherapy and sex therapy.</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h5><span class="__italic" style="color:rgb(38,37,35)"><span class="__bold">Pharmafile: </span></span><span style="color:rgb(38,37,35)"><span class="__bold">What are the current standard of care treatment options for prostate cancer? And do you think there should be a greater focus on research into new treatments?</span></span><span class="__italic" style="color:rgb(38,37,35)"> </span></h5></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">HVP: </span>It is often argued that although lots of men get prostate cancer, it is fatal to few. This is not the case and prostate cancer is the first or second cause of male cancer death in most countries across Europe. Prostate cancer survival has improved in all EU countries in the last decade, and innovations in treatment and care across the prostate cancer pathway have offered greater opportunities to enable those affected to live longer lives. However, treatment of prostate cancer is multifaceted. The effects of hormonal treatment, for example, can include sexual dysfunction or loss of libido, and this has an impact on quality of life for not only the patient, but their partners too. Everybody should be enabled to enjoy their best possible quality of life.</p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h5><span class="__italic" style="color:rgb(38,37,35)"><span class="__bold">Pharmafile: </span></span><span style="color:rgb(38,37,35)"><span class="__bold">How successful do you think new detection measures would be in reducing mortality rates?</span></span><span class="__italic" style="color:rgb(38,37,35)"> </span></h5></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">HVP: </span>If EU member states implement the recommendations for risk-based screening for prostate cancer, the result on mortality rates could have a substantial impact, with the aim being that men die with the disease rather than from the disease. The opportunity <span>for improving the outcomes for patients in terms of psychosexual health could be significant too. We shouldn’t forget that treating depression as a result of side effects of treatment for late-stage cancer also costs money for health services. If we can avoid a patient reaching that stage in their treatment journey, then it’s not just important for their well-being, but it also reduces pressure on already stretched health services.</span></p></div></div><div id="outer" data-widget="heading-widget" style="background-color:transparent;padding:0px 24px 16px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Heading-module_container__uHf-4"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><h5><span class="__italic" style="color:rgb(38,37,35)"><span class="__bold">Pharmafile: </span></span><span style="color:rgb(38,37,35)"><span class="__bold">What are the most significant obstacles that need to be overcome to improve the detection and treatment of prostate cancer?</span></span><span class="__italic" style="color:rgb(38,37,35)"> </span></h5></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">HVP: </span>There are three key Calls to Action from the Let’s Talk Prostate Cancer Expert Group. The first is to prioritise prostate cancer on political agendas, to increase the knowledge and understanding of the challenges facing patients, including breaking taboos associated with prostate cancer, and the emotional and sexual health burden of the disease.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 56px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p>The second obstacle is healthcare inequalities. We’re calling for policymakers in Europe to support research into the inequalities that affect people with prostate cancer to close this gap. Finally, we are urging European governments to ensure a timely implementation of the EU Recommendation on cancer screening within national cancer plans. It’s an extremely positive step to see prostate cancer included in the screening recommendations, but we need the implementation to happen if we are to see real change.</p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 8px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__italic">This article was originally published in Pharmafocus. </span></p></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:0px 24px 32px 24px;text-align:left;font-size:100%;line-height:1.3;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__italic">References are available on request. </span></p></div></div><div id="outer" data-widget="container-widget" style="background-color:transparent;padding:0px 24px 0px 24px;min-height:auto" class="Widget-module_outer__PBh8P Container-module_outer__Ae8eB"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><div id="outer" data-widget="horizontal-rule-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P HorizontalRule-module_outer__3UqSE"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><hr style="border-top-style:solid;border-top-width:6px;border-top-color:#f80202"/></div></div><div id="outer" data-widget="paragraph-widget" style="background-color:transparent;padding:8px 0px 8px 0px;text-align:left;font-size:80%;line-height:1.5;letter-spacing:0" class="Widget-module_outer__PBh8P Paragraph-module_container__-DJUN"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%;column-count:1"><p><span class="__bold">Professor Dr Hendrik Van Poppel</span> is chair of the Policy Office of the European Association of Urology, co-chair of the European Cancer Organisation Inequalities Network and a member of the expert group for the <span class="__bold">Let’s Talk Prostate Cancer (LTPC)</span> initiative.</p></div></div><div id="outer" data-widget="horizontal-rule-widget" style="background-color:transparent;padding:0px 0px 0px 0px" class="Widget-module_outer__PBh8P HorizontalRule-module_outer__3UqSE"><div id="inner" style="border-radius:0px 0px 0px 0px;width:100%"><hr style="border-top-style:solid;border-top-width:6px;border-top-color:#f80202"/></div></div></div></div></div></div></div><div class="_slug__share-button__ettip"><hr/></div></div></div><div id="ControlBar" class="_slug__control-bar__Jj4LE"><div class="WrapAutoHide-module_navigation__9sdQy WrapAutoHide-module_visible__UN7GD"><div class="ControlBar-module_toc-wrapper__AF5eD"><div class="ControlBar-module_toc__mKXnp"><div class="ControlBar-module_white-blur__TGapK"><div class="ControlBar-module_toc-slider__i9fv1"></div></div><div class="ControlBar-module_control-bar__9Zqak"><button class=""><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none"><path d="M13.8287 19C13.5367 19 13.2467 18.873 13.0487 18.627L8.22066 12.627C7.92266 12.256 7.92666 11.726 8.23166 11.36L13.2317 5.35998C13.5847 4.93598 14.2157 4.87898 14.6407 5.23198C15.0647 5.58498 15.1217 6.21598 14.7677 6.63998L10.2927 12.011L14.6077 17.373C14.9537 17.803 14.8857 18.433 14.4547 18.779C14.2707 18.928 14.0487 19 13.8287 19Z" fill="white"></path></svg></button><button class=""><svg xmlns="http://www.w3.org/2000/svg" width="18" height="14" viewBox="0 0 18 14" fill="none"><path d="M6.75 0H1.125C0.503719 0 0 0.503719 0 1.125V4.5C0 5.12128 0.503719 5.625 1.125 5.625C1.74628 5.625 2.25 5.12128 2.25 4.5V2.25H6.75C7.37128 2.25 7.875 1.74628 7.875 1.125C7.875 0.503719 7.37128 0 6.75 0Z" fill="white"></path><path d="M16.875 0H11.25C10.6287 0 10.125 0.503719 10.125 1.125C10.125 1.74628 10.6287 2.25 11.25 2.25H15.75V4.5C15.75 5.12128 16.2537 5.625 16.875 5.625C17.4963 5.625 18 5.12128 18 4.5V1.125C18 0.503719 17.4963 0 16.875 0Z" fill="white"></path><path d="M16.875 7.875C16.2537 7.875 15.75 8.37872 15.75 9V11.25H11.25C10.6287 11.25 10.125 11.7537 10.125 12.375C10.125 12.9963 10.6287 13.5 11.25 13.5H16.875C17.4963 13.5 18 12.9963 18 12.375V9C18 8.37872 17.4963 7.875 16.875 7.875Z" fill="white"></path><path d="M6.75 11.25H2.25V9C2.25 8.37872 1.74628 7.875 1.125 7.875C0.503719 7.875 0 8.37872 0 9V12.375C0 12.9963 0.503719 13.5 1.125 13.5H6.75C7.37128 13.5 7.875 12.9963 7.875 12.375C7.875 11.7537 7.37128 11.25 6.75 11.25Z" fill="white"></path></svg></button><button class="" disabled=""><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none"><g opacity="0.25"><path d="M9.9995 19C9.7735 19 9.5465 18.924 9.3595 18.768C8.9355 18.415 8.8785 17.784 9.2315 17.36L13.7075 11.989L9.3925 6.62701C9.0465 6.19701 9.1145 5.56701 9.5445 5.22101C9.9755 4.87501 10.6045 4.94301 10.9515 5.37301L15.7795 11.373C16.0775 11.744 16.0735 12.274 15.7685 12.64L10.7685 18.64C10.5705 18.877 10.2865 19 9.9995 19Z" fill="white"></path></g></svg></button></div></div></div></div></div><div class="_slug__wrapper__0ZIJf"></div><div></div></div></div><script> //create a new element const terms = document.createElement('div'); //set id terms.setAttribute("id","billboard-banner"); //add the new element to html var body = document.querySelector('body'); body.appendChild(terms); document.querySelector("#billboard-banner").innerHTML = "<ins data-revive-zoneid='1569' data-revive-id='9c421b7e485bf2edfee09708a4d06e2e'></ins>"; //insert new element before header //document.body.insertAdjacentElement('afterbegin', terms); const insElement = document.querySelector("#__next"); insElement.before(terms); </script> <script async="" src="//ads.datateam.co.uk/www/delivery/asyncjs.php"></script><div class="_footer_j8nu5_1"><div class="_container_j8nu5_12"><div class="_footer-row_j8nu5_23"><div class="_footer-column_j8nu5_36 _flex-2_j8nu5_117"><div class="_footer-brand_j8nu5_43"><div class=""><img alt="Logo" loading="lazy" width="40" height="40" decoding="async" data-nimg="1" class="_footer-logo_j8nu5_57" style="color:transparent" srcSet="https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png 1x, https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png 2x" src="https://media.magloft.app/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png"/></div><div class="_content_j8nu5_67"><h3>Pharmafile</h3><p>Therapeutic areas in focus</p></div></div><div class="_footer-link-list_j8nu5_121"><div class="_block_j8nu5_129"><a class="_footer-link-item_j8nu5_92" rel="noreferrer" href="mailto:info@samedanltd.com"><div class="_form-email_1lm7t_143 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>info@samedanltd.com</span></a></div><div class="_block_j8nu5_129"><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://pwa.magloft.com/"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>www.samedanltd.com</span></a></div><a target="_blank" rel="noreferrer" class="_footer-link-item_j8nu5_92" href="http://www.samedanltd.com/page/13"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Privacy Policy</span></a><a target="_blank" rel="noreferrer" class="_footer-link-item_j8nu5_92" href="http://www.samedanltd.com/page/13"><div class="_status-info_1lm7t_87 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span>Terms of Service</span></a></div></div><div class="_footer-column_j8nu5_36 _flex-1_j8nu5_39"><div class="_footer-brand_j8nu5_43"><div class="_status-accent_1lm7t_91 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><div class="_content_j8nu5_67"><h3>Categories</h3><p>Explore our inspiring content by topic</p></div></div><div class="_footer-link-list_j8nu5_121"><a class="_footer-link-item_j8nu5_92" href="/categories/infectious-diseases"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Infectious Diseases</a><a class="_footer-link-item_j8nu5_92" href="/categories/rare-diseases"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Rare Diseases</a><a class="_footer-link-item_j8nu5_92" href="/categories/dermatology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Dermatology</a><a class="_footer-link-item_j8nu5_92" href="/categories/oncology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Oncology</a><a class="_footer-link-item_j8nu5_92" href="/categories/respiratory"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Respiratory</a><a class="_footer-link-item_j8nu5_92" href="/categories/pain"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Pain</a><a class="_footer-link-item_j8nu5_92" href="/categories/neurology"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Neurology</a><a class="_footer-link-item_j8nu5_92" href="/categories/cardiovascular"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Cardiovascular</a><a class="_footer-link-item_j8nu5_92" href="/categories/womens-health"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>Women's Health</a><a class="_footer-link-item_j8nu5_92" href="/categories/news"><div class="_nav-arrow-right_1lm7t_175 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div>News</a></div></div><div class="_footer-column_j8nu5_36 _flex-1_j8nu5_39"><div class="_footer-brand_j8nu5_43"><div class="_share-action_1lm7t_463 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><div class="_content_j8nu5_67"><h3>Social Footprints</h3><p>Follow us on our Social Media Channels</p></div></div><div class="_footer-link-list_j8nu5_121"><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://twitter.com/pharmafocus"><div class="_share-twitter_1lm7t_487 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span class="_footer-text_j8nu5_125">X</span></a><a class="_footer-link-item_j8nu5_92" target="_blank" rel="noreferrer" href="https://www.linkedin.com/company/samedan-ltd/"><div class="_share-linkedin_1lm7t_483 _footer-icon_j8nu5_58 _icon_1lm7t_1 icon"></div><span class="_footer-text_j8nu5_125">linkedin</span></a></div></div></div></div></div></div><div class="Toastify"></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"domain":"magazine.pharmafile.com","pwa":{"id":663,"publicationId":14881,"pwaOptinId":655,"domain":"magazine.pharmafile.com","config":{"access":{"concurrentLimit":null,"restrictAnonymous":null,"disableSignup":null,"disableLogin":null,"disableLoginMessage":null,"disableSearchIndexing":false,"signupUrl":null,"resetPasswordUrl":null,"isUsernameLogin":null,"disableEditProfile":null,"formUrl":null,"customMarginResetPassword":null},"push":{"google":{"serverPublicKey":"BM0A-3PI9oRiVvVNuci8EbmGIC655KFzdqh9tQxnt5n6T-oECeS2hReTgrjYtIeeK0wsWfMB6VixaHT_RxZ15J0"}},"tracking":{"facebook":{"appId":null,"pixelId":null},"google":{"measurementId":"G-L1MVP1ECDJ"},"gtm":null,"sentry":true},"payment":{"stripe":null,"bypassPayment":null,"mode":"none","external":null,"currency":null},"email":{"readerOptin":false},"firebase":null,"customHtml":{"head":"\u003clink rel=\"stylesheet\" href=\"https://use.typekit.net/nat8xfl.css\"\u003e\n\u003cscript type=\"text/javascript\" src=\"https://cdn.jsdelivr.net/npm/cookie-bar/cookiebar-latest.min.js?customize=1\u0026always=1\u0026showNoConsent=1\" onload=\"setupCookieBar();\"\u003e\u003c/script\u003e\n\u003c!-- Google Search console Verification --\u003e\n\u003cmeta name=\"google-site-verification\" content=\"1Gr9skOzVfL3FXDYTam8oONdREeoeMCoQWnlojFJHX0\" /\u003e\n\u003cstyle\u003e\n#billboard-banner { text-align:center;}\n#billboard-banner img {width:100%; max-width:970px; height:auto; position:relative; top:70px;}\n\u003c/style\u003e","body":"\u003cscript\u003e\n //create a new element\n const terms = document.createElement('div');\n //set id\n terms.setAttribute(\"id\",\"billboard-banner\");\n //add the new element to html\n var body = document.querySelector('body');\n body.appendChild(terms);\n document.querySelector(\"#billboard-banner\").innerHTML = \"\u003cins data-revive-zoneid='1569' data-revive-id='9c421b7e485bf2edfee09708a4d06e2e'\u003e\u003c/ins\u003e\"; \n //insert new element before header\n//document.body.insertAdjacentElement('afterbegin', terms);\n const insElement = document.querySelector(\"#__next\");\n insElement.before(terms);\n\u003c/script\u003e\n\u003cscript async src=\"//ads.datateam.co.uk/www/delivery/asyncjs.php\"\u003e\u003c/script\u003e"},"account":{"emailEditable":true,"customSubscriptionText":null,"customSubscriptionURL":null,"enableSubscriptionTitle":null},"checkout":null},"design":{"colors":{"backgroundColor":"#FFFFFF","primaryColor":"#1976D2","secondaryColor":"#795FF4","accentColor":"#D76FD6","infoColor":"#41638C","warningColor":"#EF9338","successColor":"#20AD27","dangerColor":"#DF4241","topMenuBackgroundColor":"#FFFFFF","topMenuHeadingTitleColor":"#000000","topMenuHeadingIconColor":null,"topMenuItemTextColor":"#000000","topMenuItemIconColor":"#000000","footerMenuBackgroundColor":"#000000","footerMenuHeadingTitleColor":null,"footerMenuHeadingTextColor":null,"footerMenuHeadingIconColor":null,"footerMenuItemTextColor":null,"footerMenuItemIconColor":null},"images":{"icon":"https://cdn.magloft.com/pwa-663/pwa/logo/3a135966-5949-4bdd-8a26-75e825872c5a.png","feature":"https://cdn.magloft.com/defaults/feature-graphic.jpg","topMenuIcon":"https://cdn.magloft.com/pwa-663/pwa/top-menu-icon/5c5d21c9-69bd-4c66-93dd-f0f8bb598a70.png","footerMenuIcon":"https://cdn.magloft.com/pwa-663/pwa/footer-menu-icon/b422c56e-036d-422f-96b0-a6c3d151026b.png","alphaChannelIcon":null},"fonts":{"heading":"roboto-slab","body":"open-sans","ui":"roboto","topMenuTitle":"roboto-slab","topMenuItems":null,"topMenuSubtitle":null,"footerMenuTitle":"roboto-slab","footerMenuItems":null},"menuItems":{"collections":{"title":"Issues"},"articles":{"title":null},"account":{"title":null},"icons":{"enabled":true}},"footerShape":"flat","issueCoverAspectRatio":0.75,"fullscreenCollectionView":"auto","customOverlayToggleView":false,"defaultViewMode":"html","categories":"flat","purchaseList":true,"libraryList":false,"noteList":false,"textToSpeech":false},"layout":{"banners":[{"image":"https://cdn.magloft.com/pwa-663/pwa/banner/994f2837-a9d2-437b-92bc-e0b130e07bf6.png","title":"Pharmafile Magazine","isHidden":true,"action":{"type":"url","href":"https://www.pharmafile.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}],"bottomBanners":[{"image":"https://cdn.magloft.com/pwa-663/pwa/banner/f3f87ce8-ef8e-4547-b63f-f4805a25e350.png","title":"Samedan","isHidden":false,"action":{"type":"url","href":"http://www.samedanltd.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}],"columnSeparator":"shadow","tabs":[{"route":"","title":"Home","icon":"menu-home","visible":true},{"route":"/articles","title":"Articles","icon":"menu-articles","visible":true},{"route":"/collections","title":"Collections","icon":"menu-issues","visible":true},{"route":"/account","title":"Account","icon":"menu-account","visible":true}],"topMenu":{"showLogo":true,"showSubtitle":true,"showTitle":false,"height":"64px"},"navbar":{"animation":false,"style":"logo-left"},"sections":[{"fullWidth":true,"backgroundColor":"transparent","columnSeparator":"none","columns":[{"size":5,"blocks":[{"type":"banner","image":"https://cdn.magloft.com/pwa-663/pwa/banner/994f2837-a9d2-437b-92bc-e0b130e07bf6.png","isHidden":true,"title":"Pharmafile Magazine","action":{"type":"url","href":"https://www.pharmafile.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}]}]},{"fullWidth":false,"backgroundColor":null,"columnSeparator":"shadow","columns":[{"size":8.5,"blocks":[{"type":"issue-slider","condition":null,"color":"#F50D0D","title":"Latest Issues","issueIds":[51652,50092,47546,47328],"thumbnail":{"style":"overlay","size":"tall"},"borderRadius":null,"zoomOnHover":true,"issues":null},{"type":"article-list","condition":null,"color":"#000000","title":"Trending","variant":"variant-b","articleIds":[258239,258236,258240,258242,258238,258237],"articles":null},{"type":"article-category","condition":null,"color":"#F50D0D","title":"Rare Diseases","variant":"variant-b","categoryId":42211,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/62a51415-ed19-4d78-8601-68087122c29b.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Infectious Diseases","variant":"variant-a","categoryId":42331,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/253ea686-a135-4a29-b1a2-f8a0b400a4f5.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Dermatology","variant":"variant-a","categoryId":42212,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-list","condition":null,"color":"#195AA6","title":"Pain","variant":"variant-a","articleIds":[183367,183366,183365],"articles":null}]},{"size":3.5,"blocks":[{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Pharmafile Archive","description":"Browse older editions","action":{"type":"url","href":"https://en.calameo.com/subscriptions/6188509","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[1974],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Sign up to our Newsletters","description":"Sign up to our newsletters and digital magazines","action":{"type":"url","href":"https://curwoodcmsltd.formstack.com/forms/samedan","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"guide-install","color":"#195AA6","title":"How to Install","condition":null},{"type":"ad","title":"Advertisement","advertisementIds":[2235],"adCampaignId":null,"condition":null}]}]},{"fullWidth":true,"backgroundColor":"transparent","columnSeparator":"none","columns":[{"size":5,"blocks":[{"type":"banner","image":"https://cdn.magloft.com/pwa-663/pwa/banner/f3f87ce8-ef8e-4547-b63f-f4805a25e350.png","isHidden":false,"title":"Samedan","action":{"type":"url","href":"http://www.samedanltd.com/","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}}]}]}],"columns":[{"size":8.5,"blocks":[{"type":"issue-slider","condition":null,"color":"#F50D0D","title":"Latest Issues","issueIds":[51652,50092,47546,47328],"thumbnail":{"style":"overlay","size":"tall"},"borderRadius":null,"zoomOnHover":true,"issues":null},{"type":"article-list","condition":null,"color":"#000000","title":"Trending","variant":"variant-b","articleIds":[258239,258236,258240,258242,258238,258237],"articles":null},{"type":"article-category","condition":null,"color":"#F50D0D","title":"Rare Diseases","variant":"variant-b","categoryId":42211,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/62a51415-ed19-4d78-8601-68087122c29b.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Infectious Diseases","variant":"variant-a","categoryId":42331,"backgroundColor":null,"image":"https://cdn.magloft.com/pwa-663/category/image/253ea686-a135-4a29-b1a2-f8a0b400a4f5.jpg","articles":null,"category":null},{"type":"article-category","condition":null,"color":"#E2001A","title":"Dermatology","variant":"variant-a","categoryId":42212,"backgroundColor":null,"image":null,"articles":null,"category":null},{"type":"article-list","condition":null,"color":"#195AA6","title":"Pain","variant":"variant-a","articleIds":[183367,183366,183365],"articles":null}]},{"size":3.5,"blocks":[{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Pharmafile Archive","description":"Browse older editions","action":{"type":"url","href":"https://en.calameo.com/subscriptions/6188509","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"ad","title":"Advertisement","advertisementIds":[1974],"adCampaignId":null,"condition":null},{"type":"cta","condition":null,"icon":"symbol-bell","color":"#195AA6","title":"Sign up to our Newsletters","description":"Sign up to our newsletters and digital magazines","action":{"type":"url","href":"https://curwoodcmsltd.formstack.com/forms/samedan","target":"_blank","pwaSubscriptionId":null,"pwaSubscription":null,"optinId":null,"optin":null}},{"type":"guide-install","color":"#195AA6","title":"How to Install","condition":null},{"type":"ad","title":"Advertisement","advertisementIds":[2235],"adCampaignId":null,"condition":null}]}]},"seo":{"home":{"title":"Pharmafile - Therapeutic Areas in focus","description":"Pharma and healthcare legal \u0026 regulatory requirements, financial trends, research, tech, innovation, market insights, analysis, case studies and more","image":"https://cdn.magloft.com/pwa-663/seo/image/9a7a0d77-c45b-4ca4-8317-060aec365417.png","imageAlt":"Pharmafile magazine covers"},"articles":{"title":"Pharmafile Articles","description":"In depth articles covering AI Drug Discovery, Biomarkers, Drug Development, Clinical Trials, Personalised Medicine, Gene Editing, Biosimilars, Market Access, Real World Data, Wearables/ Interventional Devices and Patient Experience","image":"https://cdn.magloft.com/pwa-663/seo/image/a32f5169-eb7c-4073-9c9c-517e7c19e85d.png","imageAlt":"Pharmafile - Articles"},"issues":{"title":"Editions of Pharmafile","description":"Pharmafile includes in depth analysis of therapy areas including: Oncology, Pain Management, Respiratory Diseases, Rare Diseases, Cardiovascular \u0026 Metabolic, Neurological Disorders","image":"https://cdn.magloft.com/pwa-663/seo/image/48839896-f6a6-4404-8744-5e2ef6e70111.png","imageAlt":"Pharmafile - Issues"},"account":{"title":"Pharmafile - Account","description":"Manage your Pharmafile Reader Account...","image":"https://cdn.magloft.com/pwa-663/seo/image/898ff4a9-6db8-47f0-b26b-e2774d221dc2.png","imageAlt":"Reader Account"}},"strings":{"app":{"title":"Pharmafile","subtitle":"Therapeutic areas in focus"},"social":{"facebook":null,"twitter":"https://twitter.com/pharmafocus","linkedin":"https://www.linkedin.com/company/samedan-ltd/","youtube":null,"instagram":null},"topMenu":{"title":null,"subtitle":"Therapeutic areas in focus"},"footerMenu":{"title":"Pharmafile","subtitle":null,"description":null,"email":["info@samedanltd.com"],"privacyUrl":"http://www.samedanltd.com/page/13","termsUrl":"http://www.samedanltd.com/page/13","links":[{"name":"www.samedanltd.com","url":"https://pwa.magloft.com/"}]},"pages":null},"customFonts":[],"phrases":{},"trialEndAt":null,"bypassSubscription":false},"publication":{"id":14881,"title":"Pharmafile","properties":{"subtitle":null,"appIcon":"images/defaults/app-icon.png","promotionalText":null,"companyName":null,"emailReplyTo":"","privacyUrl":null,"termsUrl":null}},"categories":[{"id":42210,"slug":"infectious-diseases","title":"Infectious Diseases","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42211,"slug":"rare-diseases","title":"Rare Diseases","color":"#444444","issueCount":0,"articleCount":16,"categoryGroupIds":[]},{"id":42212,"slug":"dermatology","title":"Dermatology","color":"#444444","issueCount":0,"articleCount":6,"categoryGroupIds":[]},{"id":42331,"slug":"oncology","title":"Oncology","color":"#444444","issueCount":0,"articleCount":11,"categoryGroupIds":[]},{"id":42332,"slug":"respiratory","title":"Respiratory","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42333,"slug":"pain","title":"Pain","color":"#444444","issueCount":0,"articleCount":3,"categoryGroupIds":[]},{"id":42334,"slug":"neurology","title":"Neurology","color":"#444444","issueCount":0,"articleCount":6,"categoryGroupIds":[]},{"id":42335,"slug":"cardiovascular","title":"Cardiovascular","color":"#444444","issueCount":0,"articleCount":5,"categoryGroupIds":[]},{"id":48101,"slug":"womens-health","title":"Women's Health","color":"#444444","issueCount":0,"articleCount":4,"categoryGroupIds":[]},{"id":42404,"slug":"news","title":"News","color":"#444444","issueCount":0,"articleCount":31,"categoryGroupIds":[]}],"pwaSubscriptions":[],"categoryGroups":[],"slug":"prostate-cancer-new-screening-measures-and-decreasing-mortality","article":{"id":237758,"slug":"prostate-cancer-new-screening-measures-and-decreasing-mortality","issueId":50092,"categoryIds":[42331],"title":"Prostate cancer: new screening measures and decreasing mortality rates","description":"Professor Hendrik van Poppel talks to Pharmafile about new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what obstacles still need to be addressed in treatment","image":"https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg","cover":"https://cdn.magloft.com/publication-14881/screenshots/articles/237758.jpg?ts=1696243781","date":1696201200000,"unlockType":"free","categories":[],"pdfPageId":"Q0OfItVk9I9D","visible":true,"showOnToc":true,"bookmark":false,"position":27,"publicationId":14881,"pwaOptinId":null,"seoDescription":"Professor hendrik van poppel talks to pharmafile about new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what","classificationIds":[],"pwaSubscriptionIds":[],"source":"typeloft2","trending":false,"html":"\u003cpage-widget padding=\"16 0 24 0\"\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eONCOLOGY\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h2\"\u003e\u003cspan style=\"font-family: \u0026quot;Roboto Slab\u0026quot;;\" class=\"__bold\"\u003eProstate cancer: new screening measures and decreasing mortality rates\u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\"\u003e\u003cspan style=\"color: rgb(0, 169, 158);\"\u003eProfessor Hendrik Van Poppel talks to \u003c/span\u003e\u003cspan class=\"__italic\" style=\"color: rgb(0, 169, 158);\"\u003ePharmafile \u003c/span\u003e\u003cspan style=\"color: rgb(0, 169, 158);\"\u003eabout new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what obstacles still need to be addressed in treatment\u003c/span\u003e\u003c/span\u003e\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h5\"\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003eTell us about the new screening measures that the Let’s Talk Prostate Cancer (LTPC) Expert Group is suggesting should be implemented across the EU.\u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\"\u003eProfessor Dr Hendrik Van Poppel (HVP): \u003c/span\u003eProstate cancer is the most frequently diagnosed cancer among men in Europe but, if it is caught in the early stages, patients are able to access additional treatment options and experience more manageable side effects. Effective early detection is paramount in reducing the morbidity and mortality rate of prostate cancer.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eSo, publication of Europe’s \u003cspan class=\"__italic\"\u003eBeating Cancer Plan \u003c/span\u003eand of the updated EU cancer screening guidelines, along with the renewed focus on EU health policy, all mark important steps towards the eradication of inequalities in cancer diagnosis and treatment.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eThe new screening guidelines should support Member States in ensuring that 90% of the EU population who qualify for breast, cervical and colorectal cancer screenings are offered such screening by 2025. For the first time, the new recommendation calls for population-based organised cancer screening to include lung, prostate and, under certain circumstances, gastric cancers.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eThis is why we are making an urgent call for EU member states to implement risk-based prostate cancer screening recommendations in national cancer plans, because outcomes for future patients of prostate cancer would improve if this step is prioritised by national policymakers.\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h5\"\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003eWhat are the reasons behind the poor uptake in prostate cancer screening?\u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\"\u003eHVP: \u003c/span\u003eThere has been a relative decline in prostate specific antigen (PSA)-based population screening programmes for prostate cancer in Europe. The most important issue was the overdiagnosis and overtreatment of prostate cancer, which in 2012 led the US Preventive Services Taskforce to recommend against PSA testing.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eSadly, this now means we are seeing higher rates of metastatic disease and advanced prostate cancer at time of diagnosis, which in turn is associated with an increase in mortality and poorer quality of life. The situation is compounded by men feeling uncomfortable to talk about their health or to take the initiative. In many cases, they may not be aware of what their prostate is or the need to be aware of their health, particularly as they age, or if they are part of high-risk groups such as Black men and men with a family history of the disease.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eThe new cancer screening recommendation is based on PSA testing to identify men at high risk of disease. These men would not undergo biopsy immediately (as before) but would receive an MRI at follow-up and this, combined with active surveillance, is expected to significantly reduce overdiagnosis and overtreatment.\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h5\"\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003eAs the most frequently diagnosed cancer in men, what is leading to the increased mortality from prostate cancer? And what can be done to combat this?\u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\"\u003eHVP: \u003c/span\u003eThe COVID-19 pandemic had a significant impact on prostate cancer as it delayed both screening and treatment for patients, resulting in a record number of advanced prostate cancer cases. In fact, a recent report from the \u003cspan class=\"__italic\"\u003eLancet Oncology Commission \u003c/span\u003estates that the disastrous effects of the pandemic on early diagnosis and treatment could set back cancer outcomes in Europe by almost a decade, making urgent action a crucial priority.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003eCoupled with this, prostate cancer has been relatively low on the health policy agenda of the EU. Early detection is absolutely critical to improve patient outcomes and reduce mortality. It’s important that we work with national and international policymakers to prioritise prostate cancer on political agendas and dismantle stigma around the disease – it’s often viewed as an ‘old man’s disease’, or men just simply think it won’t happen to them, but prostate cancer is a killer. To do this we need to ensure there are better resources so patients, partners and families can be fully informed about prevention, diagnosis, treatment and ongoing care. It is only by detecting cancer at earlier stages that it will be possible to reduce mortality and improve the quality of life of patients.\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h5\"\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003eWhich factors will be assessed by a risk-based screening system? And how can this ensure that as many cases of prostate cancer as possible are detected?\u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\"\u003eHVP: \u003c/span\u003eThe new recommendations mean prostate cancer screening should be systematically implemented, using PSA testing and magnetic resonance \u003cspan\u003eimaging (MRI) scanning as a follow-up, in males at greater risk of prostate cancer. The screening recommendation is paying particular attention to equal access to screening and targeting the needs of particular socio-economic groups, people with disabilities and people living in rural or remote areas. Helpfully, the use of new technologies such as AI can enable the rapid processing of health data, which supports better targeted screening and may ultimately lead to quicker diagnoses.\u003c/span\u003e\u003c/paragraph-widget\u003e\u003cimage-widget padding=\"8 24 16 24\" aspect-ratio=\"0.7543478260869565\" magnify-label=\"center\" source=\"https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg#image/jpeg\"\u003e\u003c/image-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h5\"\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003eWhat are the greatest risk factors of prostate cancer? And should there be more focus on spreading awareness of these factors to help with early detection?\u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\"\u003eHVP: \u003c/span\u003eThe greatest risk factors for prostate cancer are age, being a Black man of African or Caribbean descent or having a family history of the disease. Unfortunately, studies show that an increasing proportion of individuals are diagnosed with metastatic or late-stage prostate cancer, so raising awareness is vital if we are to see the situation improve. In addition, ensuring the new cancer screening recommendations are implemented in full by every country within the EU will be critical alongside supporting health systems to treat patients holistically, with multidisciplinary teams and complementary therapies, like counselling, physiotherapy and sex therapy.\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h5\"\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003eWhat are the current standard of care treatment options for prostate cancer? And do you think there should be a greater focus on research into new treatments?\u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\"\u003eHVP: \u003c/span\u003eIt is often argued that although lots of men get prostate cancer, it is fatal to few. This is not the case and prostate cancer is the first or second cause of male cancer death in most countries across Europe. Prostate cancer survival has improved in all EU countries in the last decade, and innovations in treatment and care across the prostate cancer pathway have offered greater opportunities to enable those affected to live longer lives. However, treatment of prostate cancer is multifaceted. The effects of hormonal treatment, for example, can include sexual dysfunction or loss of libido, and this has an impact on quality of life for not only the patient, but their partners too. Everybody should be enabled to enjoy their best possible quality of life.\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h5\"\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003eHow successful do you think new detection measures would be in reducing mortality rates?\u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\"\u003eHVP: \u003c/span\u003eIf EU member states implement the recommendations for risk-based screening for prostate cancer, the result on mortality rates could have a substantial impact, with the aim being that men die with the disease rather than from the disease. The opportunity \u003cspan\u003efor improving the outcomes for patients in terms of psychosexual health could be significant too. We shouldn’t forget that treating depression as a result of side effects of treatment for late-stage cancer also costs money for health services. If we can avoid a patient reaching that stage in their treatment journey, then it’s not just important for their well-being, but it also reduces pressure on already stretched health services.\u003c/span\u003e\u003c/paragraph-widget\u003e\u003cheading-widget padding=\"0 24 16 24\" type=\"h5\"\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003ePharmafile: \u003c/span\u003e\u003c/span\u003e\u003cspan style=\"color: rgb(38,37,35)\"\u003e\u003cspan class=\"__bold\"\u003eWhat are the most significant obstacles that need to be overcome to improve the detection and treatment of prostate cancer?\u003c/span\u003e\u003c/span\u003e\u003cspan class=\"__italic\" style=\"color: rgb(38,37,35)\"\u003e \u003c/span\u003e\u003c/heading-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__bold\"\u003eHVP: \u003c/span\u003eThere are three key Calls to Action from the Let’s Talk Prostate Cancer Expert Group. The first is to prioritise prostate cancer on political agendas, to increase the knowledge and understanding of the challenges facing patients, including breaking taboos associated with prostate cancer, and the emotional and sexual health burden of the disease.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 56 24\"\u003eThe second obstacle is healthcare inequalities. We’re calling for policymakers in Europe to support research into the inequalities that affect people with prostate cancer to close this gap. Finally, we are urging European governments to ensure a timely implementation of the EU Recommendation on cancer screening within national cancer plans. It’s an extremely positive step to see prostate cancer included in the screening recommendations, but we need the implementation to happen if we are to see real change.\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 8 24\"\u003e\u003cspan class=\"__italic\"\u003eThis article was originally published in Pharmafocus. \u003c/span\u003e\u003c/paragraph-widget\u003e\u003cparagraph-widget padding=\"0 24 32 24\"\u003e\u003cspan class=\"__italic\"\u003eReferences are available on request. \u003c/span\u003e\u003c/paragraph-widget\u003e\u003ccontainer-widget padding=\"0 24 0 24\"\u003e\u003chorizontal-rule-widget color=\"#f80202\" width=\"6\"\u003e\u003c/horizontal-rule-widget\u003e\u003cparagraph-widget padding=\"8 0 8 0\" line-height=\"1.5\" font-size=\"80\"\u003e\u003cspan class=\"__bold\"\u003eProfessor Dr Hendrik Van Poppel\u003c/span\u003e is chair of the Policy Office of the European Association of Urology, co-chair of the European Cancer Organisation Inequalities Network and a member of the expert group for the \u003cspan class=\"__bold\"\u003eLet’s Talk Prostate Cancer (LTPC)\u003c/span\u003e initiative.\u003c/paragraph-widget\u003e\u003chorizontal-rule-widget color=\"#f80202\" width=\"6\"\u003e\u003c/horizontal-rule-widget\u003e\u003c/container-widget\u003e\u003c/page-widget\u003e","keywordPhrase":"Prostate cancer: new screening measures and","articleAssets":[{"url":"https://cdn.magloft.com/reader/fonts/roboto-slab.css","extension":"css","contentType":"text/css"},{"url":"https://cdn.magloft.com/reader/fonts/open-sans.css","extension":"css","contentType":"text/css"},{"url":"https://cdn.magloft.com/pdf-import/921/images/img_33-1.jpg","extension":"jpeg","contentType":"image/jpeg"}]},"publicationId":14881},"__N_SSG":true},"page":"/domains/[domain]/articles/[slug]","query":{"domain":"magazine.pharmafile.com","slug":"prostate-cancer-new-screening-measures-and-decreasing-mortality"},"buildId":"1bBCYhXOG7wsYuaBifvjK","isFallback":false,"gsp":true,"scriptLoader":[]}</script></body></html>